hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report
hVIVO plc, a specialist in testing infectious and respiratory disease products using human challenge clinical trials, has reported a 16% increase in revenue for 2023 to £56m. The company, listed
Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation
An NHS trust has declared a critical incident after experiencing extreme pressure on services amid a high demand at two hospitals in Staffordshire. University Hospitals of North Midlands NHS Trust
On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a
Introduction A biotech company developing a treatment for cancer and immune disorders planned to conduct their Phase 1b clinical trial in the United States (US). They approached Venn Life Sciences
hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its audited results for the year
One in five people in England are waiting for hospital care, a survey by the Office for National Statistics suggests – a much higher proportion than official NHS figures indicate.
Phase 2 Ready orally administered p38 MAP Kinase inhibitor – a preventative therapy targeting an addressable market of more than $10 billion. POLB 001 aims to target the Cytokine Release
People are being urged to avoid under-pressure accident and emergency departments unless necessary. South Tyneside and Sunderland NHS Foundation Trust said medical teams were under huge pressure already and issued
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
